Lovaza®: Potent, pure, and proven?

MOspace/Manakin Repository

Breadcrumbs Navigation

Lovaza®: Potent, pure, and proven?

Please use this identifier to cite or link to this item: http://hdl.handle.net/10355/7300

[+] show full item record


Title: Lovaza®: Potent, pure, and proven?
Author: Baker, Nicole A.; Murdock, Nicole; Pugmire, Brooke
Keywords: omega-3 products
coronary artery disease
Date: 2008-03
Publisher: Family Physicians Inquiries Network
Citation: Evidence Based Practice 11(3): 10-11.
Abstract: Lovaza (omega-3-acid ethyl esters), formerly Omacor®, is a combination prescription formulation of 465 mg eicosapentaenoic acid (EPA) and 375 mg docosahexaenoic acid (DHA) approved in the United States for the treatment of patients with hypertriglyceridemia (≥500 mg/dL). One study has shown efficacy with Lovaza for secondary prevention of coronary heart disease (CHD) events. Over-the-counter (OTC) omega-3 products have been studied more widely and have demonstrated efficacy in both primary and secondary prevention.
URI: http://hdl.handle.net/10355/7300

This item appears in the following Collection(s)

[+] show full item record